Tagged with Organon

Global With the global market for generic drugs expected to reach USD 36.4 billion by 2027 and grow at a CAGR of 5.6 percent over the period 2020-2027, it is not surprising that a number of generics producers continue to rank among the world’s top pharma companies. A look at the…

Global In spite of the spectacular healthcare advances the world has seen in recent decades and increasing evidence that gender equality is not only an ethical necessity, but a decisive component of economic and social development, disparities in women’s health persist. At the World Economic Forum annual meeting in Davos, diverse…

Italy Nicoletta Luppi, MSD Italia’s Senior Vice President & Managing Director details the need for healthcare reform in Italy and walks us through MSD’s portfolio priorities. In addition, she explains the Italian affiliate’s Equity and Inclusion initiatives.  Since the Organon spinoff, the strategy to focus on specific parts of the portfolio…

Europe Organon’s general manager for Spain and Portugal, Juan Vera, explains the challenges of executing the spinoff from MSD in the middle of the pandemic, the reasons why his affiliate has become the largest in Europe by revenue and the fourth globally after the US, China and Japan. In addition, Vera…

Europe Merck Sharp & Dohme (MSD) Spain’s Ana Argelich Hesse comments on how the big changes experienced by the global organization in 2021, including a new CEO and the spinoff of Organon, have impacted the American giant’s local strategy. Argelich Hesse also discusses regulatory changes in the Spanish market, Spain’s importance…

Italy Organon Italy’s Alper Alptekin introduces the newly formed women’s health company, his priorities for the Italian affiliate, and how improvements in women’s health can improve gender equality and give women the ability to be stronger, more vocal, and more independent.   While Organon’s portfolio is meeting the needs of women,…

Global In June 2021, as part of a broader restructuring, Merck (MSD globally) spun off its women’s health, legacy products, and biosimilars businesses. The new company formed, Organon, is positioning itself as “the only player of its size (USD 6.3 billion in revenues for 2021, 9,000 employees) focused on women’s health…